Several second-generation agents targeting AR signalling, including enzalutamide6, abiraterone7, and darolutamide8, can be used to treat mCRPC, but nearly all affected men will also develop resistance to these agents3–5 and there is an urgent need to discover new ways to treat prostate cancer. Here, AR is linked to prostate carcinoma.